Roche Details $50B US Expansion, AI R&D Focus

Swiss pharmaceutical giant Roche has announced a $50 billion investment in the United States over the next five years, aimed at expanding research, development, and manufacturing capabilities in California, Indiana, Massachusetts, and Pennsylvania. The initiative will create over 12,000 jobs and includes new R&D centers focused on artificial intelligence and next-generation medicines, along with major upgrades to current facilities. Roche's expansion is widely interpreted as a response to President Trump's tariff threats and efforts to encourage domestic pharmaceutical manufacturing. The company stated that the move will enable it to export more medicines from the US than it imports, demonstrating its commitment to the American market. Other European firms like Novartis are also increasing US investment, while European leaders warn of diminished industry capacity in Europe. Roche’s CEO reaffirmed the company's global outlook and dedication to innovation benefiting both US and global patients.